



NEPHRO CARE INDIA LIMITED

(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)

CIN: L85100WB2014PLC202429

*Regd. Office- Flat No-1 JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,
Sai Complex, North 24 Parganas, Kolkata - 700106, West Bengal, India.*

Web: <https://www.nephrocareindia.com/>

Email id: cs@nephrocareindia.com

Date: 12/11/2025

To
The Manager – Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

Symbol: **NEPHROCARE**

Dear Sir/ Madam,

Sub: Press Release – Nephro Care India Limited posts PAT of Rs 1.94 crore in H1FY25 - 26

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the communication being released by the Company to the Press titled as “**Multi-speciality healthcare provider Nephro Care India Limited posts PAT of Rs 1.94 crore in H1FY25 - 26.**”

We request you to take the above on record.

Thanking You.

For Nephro Care India Limited

Sougata Sengupta
Company Secretary &
Compliance Officer

Encl.: As above



Multi-speciality healthcare provider Nephro Care India posts PAT of Rs 1.94 crore in H1FY25 - 26

- EBITDA stood at Rs 5.02 crore in H1FY25 – 26
- Company bullish about further improvement in revenue as its newly inaugurated multispeciality hospital – Vivacity would contribute significant revenue in the second half of this fiscal
- NCIL, which currently has four comprehensive renal care clinics, plans to set up two more by the end of this fiscal

Kolkata, November 12, 2025: Deepak Parekh-backed **Nephro Care India Limited (NCIL)**, a leading multi-specialty healthcare provider, has announced a robust performance for the half year ended September 30, 2025, driven by strong revenue growth and expanding operations.

The company reported a **33.71% rise in standalone net profit** to **₹1.94 crore** for H1 FY 2025–26, compared to **₹1.45 crore** in H2 FY 2024–25. Revenue from operations grew **38.76%** to **₹39.33 crore**, up from **₹28.34 crore** in the previous half year.

Operating profit (**EBITDA**) stood at **₹5.02 crore**, reflecting an **EBITDA margin of 12.57%** for the period. The company remains optimistic about further improvement in profitability as its multi-specialty hospital, **Vivacity**, achieves operational breakeven and begins contributing to consolidated performance.

Commenting on the company's results, **Dr. Pratim Sengupta**, Founder, MD & CEO of Nephro Care India, said:

“We are pleased with the strong topline growth in H1 FY 2025–26, which underscores our commitment to making renal care more accessible and affordable across India. While our margins have been temporarily impacted due to the initial costs associated with our new hospital, Vivacity, we expect significant improvement in profitability in the coming quarters as operations stabilize. India continues to face a shortage of specialized renal care infrastructure, and our goal is to bridge this gap by expanding our network of advanced renal care clinics nationwide.”

With a mission to deliver **comprehensive renal care**, NCIL offers an integrated framework covering clinical, lifestyle, and wellness dimensions. The company operates through programs such as **Mukti**, **Home Dialysis**, **Home Care**, and **Diagnostics**, ensuring holistic patient engagement and rehabilitation.

NCIL's clinics operate under a **'hub-and-spoke' model**, each independently equipped with advanced infrastructure and skilled medical professionals, ensuring high-quality, patient-centric care across regions.

About Nephro Care India Limited (NCIL):

Nephro Care India Limited is a leading healthcare organization committed to providing accessible, affordable, and advanced renal care across India. Backed by a multidimensional patient engagement framework, NCIL integrates modern medicine with holistic wellness practices to enhance patient outcomes and quality of life